Genomictree Inc.
228760
주식 순위
#19173
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
주가
$6.61
시가총액
$162.26M
변동 (1일)
1.06%
변동 (1년)
-50.87%
국가
KR
거래 Genomictree Inc. (228760)
카테고리
Healthcare
의 시가총액 Genomictree Inc.(228760)
시가총액: $162.26M
October 2026 기준으로 Genomictree Inc.의 시가총액은 $162.26M입니다. 이는 당사 데이터에 따르면 Genomictree Inc.이 세계에서 19173rd번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2017부터 2026까지 Genomictree Inc.의 시가총액 기록
